Recent briefings noted broad equity market movement in the period surrounding this report, with the Nasdaq 100 adding approximately $3.5 trillion in market capitalisation over four consecutive trading sessions through mid-August 2026, attributed to strong corporate earnings and renewed interest in technology sectors [Brief - 2026-09-27] [Brief - 2026-09-19] [Brief - 2026-09-11]. This backdrop formed part of the market environment within which CVS Health Corp. trading activity occurred during the third quarter of 2026.
As of 30 June 2026, CVS Health Corp. reported trailing twelve-month revenue of approximately $415.1 billion, representing year-over-year revenue growth of 7.26% [SEC 10-Q - CVS - 2026-06-30]. Net income on a TTM basis stood at approximately $4.9 billion, with a net margin of 1.18% and an operating margin of 1.997%. Gross margin was recorded at 7.06%. EPS growth on a year-over-year basis was 188.75%, while the P/E ratio stood at 22.81. The company held approximately $11.3 billion in cash against total debt of approximately $63.5 billion, producing a market capitalisation of approximately $110.5 billion [SEC 10-Q - CVS - 2026-06-30].
Institutional ownership activity was the primary trigger for this report. Four significant institutional investors opened new positions in CVS during the most recent 13F reporting period. Citadel (Ken Griffin), AQR Capital (Cliff Asness), Millennium (Izzy Englander), and Bridgewater (Ray Dalio) each initiated new holdings in the company [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026]. No insider transaction data was available for inclusion in this report.
The prevailing macroeconomic rate environment as of the report date showed the 10-year US Treasury yield (DGS10) at 5.24% and the 2-year yield (DGS2) at 4.78%, producing a normal yield curve configuration with a 46 basis point spread between the two tenors [FRED DGS10] [FRED DGS2]. This rate environment is relevant context for a company carrying approximately $63.5 billion in total debt, as financing costs and refinancing conditions remain a factor in the broader financial profile of capital-intensive healthcare and pharmacy benefit businesses.